Fundraising FoxAloe Therapeutics
Darnestown, US · Founded 2020 · 1 known investors
Find your way into Aloe Therapeutics
Sign up to see every warm intro you have to Aloe Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aloe Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at a tumor site during biopsy or resection surgery to activate the immune system and make patients more responsive to checkpoint immunotherapy. It targets advanced solid tumors across multiple tumor types and disease stages.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$100K disclosed across 1 round · 2024
▶$100KraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martha SklavosExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Aloe Therapeutics.
Frequently asked questions
- What does Aloe Therapeutics do?
- Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at a tumor site during biopsy or resection surgery to activate the immune system and make patients more responsive to checkpoint immunotherapy. It targets advanced solid tumors across multiple tumor types and disease stages.
- Who are Aloe Therapeutics's investors?
- Aloe Therapeutics's investors include The Innovation Space.
- How much funding has Aloe Therapeutics raised?
- Aloe Therapeutics has disclosed $100K raised across 1 round.
- Where is Aloe Therapeutics headquartered?
- Aloe Therapeutics is headquartered in Darnestown, US.